The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Benjamin Rolles(Brigham and Women's Hospital), Angela Consagra(Azienda Ospedaliero-Universitaria Careggi), Andrew M. Brunner(Harvard University), Yasmin Abaza(Northwestern University), Gail J. Roboz(Cornell University), Ιoannis Kotsianidis(Democritus University of Thrace), Anoop Enjeti(Hunter Medical Research Institute), Hetty E. Carraway(Cleveland Clinic), Hayley Hawkins(Vanderbilt University Medical Center), David Valcárcel(Vall d'Hebron Hospital Universitari), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), David A. Sallman(Moffitt Cancer Center), Constantine Logothetis(Saint Louis University), Amy E. DeZern(Johns Hopkins University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Tariq Kewan(Yale University), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Somedeb Ball(Vanderbilt University), Torsten Haferlach(Martin Luther Christian University), Jessica M. Stempel(University of New Haven), Zhuoer Xie(Mayo Clinic), José González Campos(Catholic University of the Maule), Ondřej Bláha(Yale University), Michael R. Savona(Vanderbilt University), Lisa Pleyer(Paracelsus Medical University), Mikkael A. Sekeres(University of Miami), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Theodore Getz(University of New Haven), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Najla Al Ali(Moffitt Cancer Center), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Khalid Halahleh(King Hussein Cancer Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Christine M. McMahon(Albert Einstein College of Medicine), Pinkal Desai(NewYork–Presbyterian Hospital), Talha Badar(Mayo Clinic in Florida), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Jaroslaw P. Maciejewski(Cleveland Clinic), Justin Grenet(Cornell University), Luca Lanino(Humanitas University), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Rory M. Shallis(Smilow Cancer Hospital), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Maria Amaya(University of Colorado Anschutz Medical Campus), Vassiliki Pappa(University General Hospital Attikon), Kamal Al-Rabi(King Hussein Cancer Center), Aram Bidikian(University of New Haven), Samuel Urrutia(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k